{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:56Z","timestamp":1786119296509,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/inf.0b013e31818ffd03","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T10:27:14Z","timestamp":1242901634000},"page":"267-272","source":"Crossref","is-referenced-by-count":48,"title":["Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children"],"prefix":"10.1097","volume":"28","author":[{"given":"Katia","family":"Abarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve A.","family":"Losonsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 11","key":"R1-2-20210202","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1097\/01.inf.0000144662.86396.07","article-title":"The changing epidemiology of respiratory syncytial virus and influenza: impetus for new control measures.","volume":"23","author":"Glezen","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R2-2-20210202","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/infdis\/161.3.402","article-title":"Respiratory syncytial and parainfluenza viruses.","volume":"161","author":"Heilman","year":"1990","journal-title":"J Infect Dis"},{"key":"R3-2-20210202","first-page":"199","article-title":"Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.","volume":"82","author":"Groothuis","year":"1988","journal-title":"Pediatrics"},{"key":"R4-2-20210202","article-title":"Red Book: Report of the Committee on Infectious Diseases. 25th ed.","year":"2000"},{"issue":"3","key":"R5-2-20210202","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"R6-2-20210202","article-title":"Full Prescribing Information for Synagis (Palivizumab).","year":"2006"},{"key":"R7-2-20210202","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"R8-2-20210202","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","article-title":"Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.","volume":"368","author":"Wu","year":"2007","journal-title":"J Mol Biol"},{"key":"R9-2-20210202","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jmb.2005.04.049","article-title":"Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.","volume":"350","author":"Wu","year":"2005","journal-title":"J Mol Biol"},{"key":"R10-2-20210202","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00006454-199809000-00007","article-title":"Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia.","volume":"17","author":"Saez-Llorens","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"R11-2-20210202","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","article-title":"Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia.","volume":"17","author":"Subramanian","year":"1998","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-200904000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:55:12Z","timestamp":1786038912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-200904000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31818ffd03","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}